Segui
Annabelle Biscans
Annabelle Biscans
AstraZeneca R&D, Sweden
Email verificata su astrazeneca.com
Titolo
Citata da
Citata da
Anno
Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo
A Biscans, A Coles, R Haraszti, D Echeverria, M Hassler, M Osborn, ...
Nucleic Acids Research, 2018
1472018
Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways
MF Osborn, AH Coles, A Biscans, RA Haraszti, L Roux, S Davis, S Ly, ...
Nucleic Acids Research, 2018
1122018
Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles
RA Haraszti, R Miller, MC Didiot, A Biscans, JF Alterman, MR Hassler, ...
Molecular Therapy 26 (8), 1973-1982, 2018
832018
The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo
A Biscans, A Coles, D Echeverria, A Khvorova
Journal of controlled release 302, 116-125, 2019
532019
Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 in vivo
M Segal, A Biscans, ME Gilles, E Anastasiadou, R De Luca, J Lim, ...
Molecular Therapy-Nucleic Acids 19, 267-277, 2020
452020
Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles
A Biscans, J Caiazzi, N McHugh, V Hariharan, M Muhuri, A Khvorova
Molecular Therapy 29 (4), 1382-1394, 2021
442021
Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid …
BMDC Godinho, JW Gilbert, RA Haraszti, AH Coles, A Biscans, L Roux, ...
nucleic acid therapeutics 27 (6), 323-334, 2017
442017
Hydrophobicity of lipid-conjugated siRNAs predicts productive loading to small extracellular vesicles
A Biscans, RA Haraszti, D Echeverria, R Miller, MC Didiot, M Nikan, ...
Molecular Therapy 26 (6), 1520-1528, 2018
402018
The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy
A Biscans, J Caiazzi, S Davis, N McHugh, J Sousa, A Khvorova
Nucleic Acids Research 48 (14), 7665-7680, 2020
392020
Transvascular delivery of hydrophobically modified siRNAs: gene silencing in the rat brain upon disruption of the blood-brain barrier
BMDC Godinho, N Henninger, J Bouley, JF Alterman, RA Haraszti, ...
Molecular Therapy 26 (11), 2580-2591, 2018
362018
Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in …
M Nikan, MF Osborn, AH Coles, A Biscans, BMDC Godinho, RA Haraszti, ...
Bioconjugate chemistry 28 (6), 1758-1766, 2017
362017
Exploring the emergence of RNA nucleosides and nucleotides on the early Earth
A Biscans
Life 8 (4), 57, 2018
262018
Innovative developments and emerging technologies in RNA therapeutics
F Halloy, A Biscans, KE Bujold, A Debacker, AC Hill, A Lacroix, O Luige, ...
RNA biology 19 (1), 313-332, 2022
252022
Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity
WF Lim, M Forouhan, TC Roberts, J Dabney, R Ellerington, AA Speciale, ...
Science Advances 7 (34), eabi6896, 2021
222021
Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
SM Davis, VN Hariharan, A Lo, AA Turanov, D Echeverria, J Sousa, ...
Molecular Therapy-Nucleic Acids 29, 135-149, 2022
182022
A versatile post-synthetic method on a solid support for the synthesis of RNA containing reduction-responsive modifications
A Biscans, S Rouanet, JJ Vasseur, C Dupouy, F Debart
Organic & Biomolecular Chemistry 14 (29), 7010-7017, 2016
162016
RNAi-based modulation of IFN-γ signaling in skin
Q Tang, J Sousa, D Echeverria, X Fan, YC Hsueh, K Afshari, N MeHugh, ...
Molecular Therapy 30 (8), 2709-2721, 2022
152022
Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo
A Biscans, S Ly, N McHugh, DA Cooper, A Khvorova
Journal of Controlled Release 349, 831-843, 2022
142022
Direct Synthesis of Partially Modified 2′‐O‐Pivaloyloxymethyl RNAs by a Base‐Labile Protecting Group Strategy and their Potential for Prodrug‐Based Gene …
A Biscans, M Bos, AR Martin, N Ader, G Sczakiel, JJ Vasseur, C Dupouy, ...
ChemBioChem 15 (18), 2674-2679, 2014
142014
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ...
Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023
132023
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20